# US 2026/0021080 A1 · Pharmaceutical compounds, pharmaceutical compositions, and methods of treating depression and other disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0021080 A1
- Document ID: US20260021080A1
- Status: Published application
- Kind: A1
- Application number: 19/341,358
- Filed: 2025-09-26
- Published: 2026-01-22
- Earliest claimed: 2023-03-27
- Assignees: Miralogx LLC
- Applicants: Miralogx LLC
- Inventors: Jonnie R. Williams, SR.
- Web page: https://patentgrep.com/patent/US20260021080A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- C07D 457/04: with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D 457/06: Lysergic acid amides
- C07D 457/08: in which the amide nitrogen is a member of a heterocyclic ring
- C07D 457/14: containing indolo [4, 3-f, g] quinoline ring systems condensed with carbocyclic rings or ring systems
- C07D 487/06: Peri-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

In some aspects, pharmaceutical compounds are disclosed which may be useful for treating anxiety and/or other disorders. In another aspect, a pharmaceutical composition includes a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle therefor. In yet another aspect, a method of treating anxiety, depression, obsessive-compulsive disorder, tobacco addiction, alcohol addiction, cocaine addiction, headache, cluster headache, or cancer-related or other end-of-life psychological distress involves administering the pharmaceutical composition to an individual in need thereof.

## Claims

### Claim 1

A compound having a structure of Formula (I):
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of an electron pair, H, halogen, OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, phenyl, carbonate ester, a carboxylate, a carboxyl, an ester, a hydroperoxy, a peroxy, an ether, a hemiacetal, a hemiketal, an acetal, a ketal, an orthoester, a methylenedioxy, an orthocarbonate ester, carboxamide, an amine, an imine, an amide, an azide, an azo, a cyanate, a nitrate, a nitrile, an isonitrile, a nitrosooxy, a nitro, a pyridyl, a thiol, a sulfide, sulfinyl, a sulfonyl, a thiocyanate, a carbonothioyl, a phosphate, and heterocycle; optionally wherein the alkyl, alkenyl, alkynyl or acyl is substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle; wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl; wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl; wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl; each ______ represents a single or double bond, with the proviso that within a 5-membered ring, one ______ is a double bond and the other four ______ are single bonds; or
a pharmaceutically acceptable salt or ester thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound has a structure of Formula (Ia):
or a pharmaceutically acceptable salt or ester thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound has a structure of Formula (Ib):
or a pharmaceutically acceptable salt or ester thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R3 and R4, together with the nitrogen atom to which they are attached form an optionally-substituted heterocyclic ring; or a pharmaceutically acceptable salt or ester thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is a halogen.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the halogen is selected from the group consisting of F, Cl, Br, and I, preferably wherein the halogen is Br.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or ester thereof.

### Claim 8

A compound having a structure of Formula (II):
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of an electron pair, H, halogen, OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, phenyl, carbonate ester, a carboxylate, a carboxyl, an ester, a hydroperoxy, a peroxy, an ether, a hemiacetal, a hemiketal, an acetal, a ketal, an orthoester, a methylenedioxy, an orthocarbonate ester, carboxamide, an amine, an imine, an amide, an azide, an azo, a cyanate, a nitrate, a nitrile, an isonitrile, a nitrosooxy, a nitro, a pyridyl, a thiol, a sulfide, sulfinyl, a sulfonyl, a thiocyanate, a carbonothioyl, a phosphate, and heterocycle; optionally wherein the alkyl, alkenyl, alkynyl or acyl is substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle; wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl; wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O) O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl; wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl; or a pharmaceutically acceptable salt, ester, or ether thereof.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R3 and R4, together with the nitrogen atom to which they are attached form an optionally-substituted heterocyclic ring; or a pharmaceutically acceptable salt or ester thereof.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is a halogen.

### Claim 11 (depends on 10)

The compound of claim 10, wherein the halogen is selected from the group consisting of F, Cl, Br, and I.

### Claim 12 (depends on 1)

A compound of claim 1 which has a structure of Formula (III):
or a pharmaceutically acceptable salt, ester, or ether thereof.

### Claim 13 (depends on 12)

The compound of claim 12, wherein R3 and R4, together with the nitrogen atom to which they are attached form an optionally-substituted heterocyclic ring; or a pharmaceutically acceptable salt or ester thereof.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R1 is a halogen.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the halogen is selected from the group consisting of F, Cl, Br, and I.

### Claim 16 (depends on 1)

A compound of claim 1 which has a structure selected from the group consisting of:
or a pharmaceutically acceptable salt, ester, or ether thereof.

### Claim 17

A compound having a structure selected from the group consisting of:
or a pharmaceutically acceptable salt, ester, or ether thereof.

### Claim 18 (depends on 16)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 16 and a pharmaceutically acceptable vehicle therefor.

### Claim 19 (depends on 18)

A method of treating anxiety comprising administering to an individual in need thereof the pharmaceutical composition according to claim 18.

### Claim 20 (depends on 18)

A method of treating a disorder selected from the group consisting of depression, obsessive-compulsive disorder, tobacco addiction, alcohol addiction, cocaine addiction, headache, and psychological distress, comprising administering to an individual in need thereof the pharmaceutical composition of claim 18.
